Although Non-diagnostic Between Necrosis and Recurrence, FDG PET/CT Assists Management of Brain Tumours After Radiosurgery

In Vivo. 2016 Jul-Aug;30(4):513-20.

Abstract

Aim: To re-evaluate the role of (18)F-fluoro-deoxy-D-glucose (FDG) positron emission tomography/ computer assisted tomography (PET/CT) co-registered with magnetic resonance imaging (MRI) in differentiating adverse radiation effect (ARE) from tumour recurrence after Gamma Knife radiosurgery of brain tumours.

Patients and methods: Twenty-seven PET/CT studies co-registered with MRI were performed on 16 patients after radiosurgery, with 12/16 patients having multiple radiosurgery treatments. Long term follow-up was used for evaluation, with 3/16 patients being histopathologically confirmed.

Results: PET/CT was positive in all studies in 6/16 patients, negative in all studies in 6/16 and changed from negative to positive in one. In 2/16 patients, PET/CT was both positive and negative in separate tumour foci. In 9/16 cases with a positive PET/CT, tumour was confirmed. In 6/16 patients with a negative PET/CT, 3/6 had recurrence and 3/6 ARE. In 1/16, equivocal results became negative after retreatment. PET/CT/MRI identified tumour within ARE. Sensitivity of PET/CT/MRI proved to be 64.7%, and specificity 100%.

Conclusion: PET/CT/MRI assists management, by revealing metabolism rather than histology.

Keywords: Gamma Knife; MRI; PET/CT; adverse radiation effect; brain metastases; glioma; necrosis; radiosurgery.

MeSH terms

  • Adult
  • Aged
  • Brain Neoplasms / diagnostic imaging
  • Brain Neoplasms / secondary*
  • Brain Neoplasms / surgery
  • Disease Management
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Middle Aged
  • Necrosis
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Neoplasm Recurrence, Local / pathology*
  • Neoplasm Recurrence, Local / surgery
  • Neoplasms / diagnostic imaging
  • Neoplasms / pathology*
  • Neoplasms / surgery
  • Positron Emission Tomography Computed Tomography / methods*
  • Prognosis
  • Radiopharmaceuticals*
  • Radiosurgery*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18